Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company developing, manufacturing and marketing generic, specialty and branded medicines across injectable, oral and respiratory dosage forms.
The company's portfolio spans oncology, cardiovascular, respiratory, pain management and other therapeutic areas, serving hospitals and retail markets across more than ten countries.
Hikma has recently established a dedicated UK office to strengthen medicine supply support for the NHS.
The company is listed on the London Stock Exchange and headquartered in London.
Latest News
Hikma Launches NPH Otic Solution in US with Orbicular Partnership
Hikma Pharmaceuticals has launched a sterile generic ear-drop treatment containing neomycin, polymyxin B and hydrocortisone in the United States. The product was developed by Orbicular Pharmaceutical Technologies, which holds the abbreviated new drug application, while Hikma will commercialise and distribute it. The medicine has FDA approval as a Competitive Generic Therapy for certain bacterial infections of the external ear. The announcement does not establish UK marketing approval.
Hikma Appoints ViiV's Rebecca Hall as Chief Financial Officer
Hikma has appointed Rebecca Hall, currently CFO of ViiV Healthcare, as Chief Financial Officer and Executive Director, joining in Q1 2027. Khalid Nabilsi steps down from the board on 31 December 2026 and continues as Deputy CEO for North America and Europe.